<a href="https://laohu8.com/S/SBHMY">Sino Biopharmaceutical</a> Limited Receives Acceptance for New Indication Application of Culmerciclib Capsule for First-Line Breast <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>
Sino Biopharmaceutical Limited has announced the acceptance of a new indication application for the marketing of its Culmerciclib Capsule. This capsule is designed for the first-line treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer. The application has been submitted to the Centre for Drug Evaluation of the National Medical Products Administration of the PRC and has been accepted for review. This development marks a significant step forward in the company's efforts to provide advanced treatment options for breast cancer patients. The Culmerciclib Capsule, a CDK2/4/6 inhibitor, is to be used in combination with fulvestrant injection and has undergone a Phase III clinical study to evaluate its efficacy and safety.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。